Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 3/20 | 0.45 |
| ▸ | MMP9 | P14780 | 7/20 | 0.44 |
| ▸ | MMP1 | P03956 | 4/20 | 0.44 |
| ▸ | MMP3 | P08254 | 3/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | AREG | P15514 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369530 | 1.00 | NR1D1 (0.45) | NR1D1MMP9MMP1MMP3ADAM17 | |
| SCHEMBL14001463 | 0.87 | NR1D1 (0.44) | NR1D1MMP9MMP1MMP3ADAM17 | |
| SCHEMBL6370245 | 0.87 | NR1D1 (0.58) | NR1D1MMP9MMP1MMP3ADAM17 | |
| SCHEMBL7332043 | 0.86 | CYP19A1 (0.42) | NR1D1MMP9MMP1MMP3ADAM17 | |
| SCHEMBL10445427 | 0.83 | GLA (0.45) | NR1D1MMP9MMP1MMP3ADAM17 | |
| SCHEMBL12125023 | 0.83 | ACE (0.53) | CHEK1JAK2 | |
| SCHEMBL4239788 | 0.83 | ACE (0.53) | CHEK1JAK2 | |
| SCHEMBL10067954 | 0.83 | ACE (0.53) | CHEK1JAK2 | |
| SCHEMBL12507483 | 0.82 | ACE (0.43) | NR1D1MMP9MMP1MMP3ADAM17 | |
| SCHEMBL29177033 | 0.81 | CHEK1 (0.47) | NR1D1MMP9MMP1MMP3ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | NR1D1 608/4885MMP9 3101/4885MMP1 3444/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | NR1D1 608/4885MMP9 3101/4885MMP1 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.